Fast, inexpensive test for malaria drills down to specifics

By | September 22, 2020

“This field-ready SHERLOCK diagnostic malaria assay surpasses the sensitivity and specificity requirements set by the WHO for a desired test that can be used to detect low parasite density in asymptomatic carriers of all major Plasmodium species,” said Collins. “Its highly streamlined design could provide a viable solution to the present diagnostic bottleneck on the path to eliminate malaria, and more generally enabling malaria surveillance in low-resource settings.”

Collins is a lead of the Wyss Institute’s Living Cellular Devices Focus Area, and also the Termeer Professor of Medical Engineering & Science at MIT.

Team members demonstrated their engineered SHERLOCK (specific high-sensitivity enzymatic reporter unLOCKing) assay to be capable of detecting less than two parasites per microliter of blood, the WHO’s suggested “limit of detection” (LOD) for a test with broad utility in endemic areas. Showing the assay’s clinical potential by analyzing clinical samples containing P. falciparum and P. vivax species, they called out them out with 100 percent sensitivity, by correctly identifying true positive samples, and 100 percent specificity, by also correctly identifying samples lacking a certain Plasmodium species in true negative samples.

Near 100 percent sensitivity and specificity are key attributes of diagnostic assays to be used in real-world testing. Moreover, the assay is designed so that it can also determine the presence of frequently mutated P. falciparum strains that have lost their HRP2 antigen and thus escape the detection by common rapid diagnostic tests.

Collins’ group at the Wyss Institute and MIT co-developed the SHERLOCK technology with Feng Zhang’s group at the Broad Institute. It was licensed to Sherlock Biosciences, a startup that used it to create a rapid molecular diagnostic for other disease applications, and recently received an emergency use authorization from the FDA for its COVID-19 rapid diagnostic.

Read More:  Can depression shut your body down

Other methods have been developed that, like the new SHERLOCK assay, amplify and detect the DNA (or RNA) nucleic acid material of Plasmodium species. However, to date, these methods remain limited by their need for expensive laboratory equipment.

“Importantly, the assay is compatible with different sample types, such as whole blood, plasma, serum, and dried blood, and all components required for amplification, Cas12a activation and signal generation can be lyophilized in a single test tube to work together in a one-pot-reaction after they are reconstituted and mixed with patient sample,” said first-author Rose Lee, a clinical fellow in Collins’ group and Boston Children’s Hospital. “This … allows testing to be performed in low-resource settings with minimal expertise.”

Adapted from a Wyss Institute online article.

Health & Medicine – Harvard Gazette